A cancer-therapeutics start-up aims to recruit up to 20 researchers.
Blueprint Medicines, a start-up cancer-therapeutics company based in Cambridge, Massachusetts, is to recruit up to 20 researchers. In April, the firm secured US$40 million in venture capital, the largest first-round financing deal in 2011 so far for a life-sciences company, says the US National Venture Capital Association in Arlington, Virginia. Chris Varma, co-founder of Blueprint, says that the start-up is seeking early-career and established medicinal chemists, cell and structural biologists, and bioinformaticians to help discover genomics-based therapies.
Related links
Related links
Related links in Nature Research
Start-ups: In search of venture capital
Genzyme deal set to alter biotech landscape
Related external links
Rights and permissions
About this article
Cite this article
Massachusetts openings. Nature 473, 245 (2011). https://doi.org/10.1038/nj7346-245d
Published:
Issue Date:
DOI: https://doi.org/10.1038/nj7346-245d